WO2009146082A2 - Rfid monitoring of drug regimen compliance - Google Patents

Rfid monitoring of drug regimen compliance Download PDF

Info

Publication number
WO2009146082A2
WO2009146082A2 PCT/US2009/039179 US2009039179W WO2009146082A2 WO 2009146082 A2 WO2009146082 A2 WO 2009146082A2 US 2009039179 W US2009039179 W US 2009039179W WO 2009146082 A2 WO2009146082 A2 WO 2009146082A2
Authority
WO
WIPO (PCT)
Prior art keywords
patient
rfid
ingestion
harness
rfid reader
Prior art date
Application number
PCT/US2009/039179
Other languages
French (fr)
Other versions
WO2009146082A3 (en
Inventor
Jacob Sharony
Satya Sharma
Shmuel Eynav
Milutin Stanacevic
Akshay Athalye
Original Assignee
The Research Foundation Of The State University Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Research Foundation Of The State University Of New York filed Critical The Research Foundation Of The State University Of New York
Priority to US12/936,098 priority Critical patent/US20110163871A1/en
Publication of WO2009146082A2 publication Critical patent/WO2009146082A2/en
Publication of WO2009146082A3 publication Critical patent/WO2009146082A3/en

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4833—Assessment of subject's compliance to treatment

Definitions

  • the present invention relates generally to electromagnetic tag technology and, more specifically, to the use of Radio Frequency Identification (RFID) tags to ensure and track proper drug regimen compliance and oral medication.
  • RFID Radio Frequency Identification
  • Near-field UHF provides inherently stronger inductive coupling, and although the attenuation by the body at this frequency range is higher, it provides longer range of detection, up to 1 meter, which is almost on the order of the required distance.
  • a challenge of the design of such a wireless link is the extension of distance that can be achieved through near-field UHF, since due to weak coupling between antennas only a small part of emitted power by an external transmitter antenna reaches the RFID tag antenna.
  • the present invention provides a modified design of an external reader to provide an elongated read range, via a spatially selective external reader, adopting beamforming concepts of antenna design, based on a gradient flow method, such those as described by M. Stanacevic and G.
  • the present invention overcomes the shortcomings of conventional systems by providing a focused ingestion monitoring device by use of electromagnetic tag technology RFID tags to ensure and track proper ingestion of oral medication, which is particularly relevant in hospital and long term care environments.
  • the present invention provides a wireless system for monitoring ingestion of medicine and absorption into the body to insure proper dosage control and usage.
  • an RFID tag is inserted in or affixed to the pill, and a wireless link between the RFID tag and an external reader is provided that will function when the pill is inside the body.
  • Preferred embodiments of the present invention overcome the above shortcomings of conventional systems and methods by providing an apparatus for monitoring drug regimen compliance that includes a wearable RFID reader for detecting a Radio Frequency Identification (RFID) tag affixed to an pharmaceutical agent, and for wirelessly communicating with a central monitoring system upon detection of ingestion.
  • the communication includes an identification of the ingested pharmaceutical agent.
  • a database is updated to confirm drug regimen compliance by one or a plurality of patients, in an Internet based tracking system.
  • Fig. 1 is a perspective view of a wearable RFID reader worn around the neck of a patient in accordance with a preferred embodiment of the present invention.
  • an electromagnetic RFID tag is provided on a pill, with the RFID tag providing information about the medicament when polled by the RFID reader.
  • Antennas in the RFID tag and reader could be in different sizes and shapes, with the size of the tag antenna corresponding to the size of the pill, and the external reader fashioned in a manner to accommodate wearing by the patient on his or her body.
  • a necklace/pendant is provided for the reader, as shown in Fig. 1.
  • the reader is clipped to the belt or a waistband. With such configuration a maximum achievable distance at which the reader can detect the presence of the RFID tag extends beyond the distance between the RFID tag inside the body and the external reader.
  • a gradient flow method originates from localization of traveling waves. Location of the source can be obtained as an estimation of the source direction through computation of the spatial gradients for the arrays with dimensions smaller than but comparable to the wavelength.
  • spatial gradient representation time delays are converted into relative amplitudes of the time- differentiated source signals, if the dimensions of the array are within certain bounds.
  • the gradient flow technique in the proposed spatially selective external reader is used to direct the magnetic energy into certain regions by generating spatial gradients using closely spaced antennas.
  • the present invention monitors drug regimen compliance by tracking an RFID tag ( 120) affixed to a pill ( 110), i.e. ingestible pharmaceutical agent, via a wearable RFID reader (200), preferably configured as a harness (260) worn by a patient (305), as shown in Fig. 1.
  • the RFID tag (120) includes information identifying the pharmaceutical agent (1 10) and such information is wirelessly transmitted to reader (200), which in turn provides the information, along with an identification of the patient wearing the reader (200), to an Internet based central monitoring system (400), preferably immediately upon ingestion of the pharmaceutical agent (110).
  • the central monitoring system (400) will, upon communication and confirmation of the ingestion, compare the received information to information stored in a database (410) to determine whether the patient is sufficiently compliant with a prescribed drug regimen.
  • the database (410) will identify each of a plurality of harnesses respectively worn by a plurality of patients.
  • the central monitoring system (400) will provide an overdose alarm to a caregiver.
  • an alarm is provided to a caregiver when the database is not updated at a predetermined interval, and the alarm will identify each particular patient who is not in compliance with that patient's prescribed drug regimen.
  • the caretaker will also have access to a report generated at regular intervals showing times that ingestion is detected for each patient among the plurality of patients.
  • a plurality of antenna layers is provided on the RFID tag (120), with the layers separated by a plurality of coatings that sequentially dissolve during digestion.
  • the RFID reader (200) detects whether a first layer of the RFID tag (120) has dissolved, which typically occurs upon exposure to liquid when placed in the patient's mouth.
  • an alert is preferably provided if the first layer is detected as not being dissolved at the time of detection by the RFID reader (200), via an auxiliary antenna having a denser coating that dissolves further along the gastrointestinal tract.
  • the harness (260) positions the RFID reader (200) adjacent to the patient's throat (310), and the RFID reader (200) is fixably secured to the harness (260). Further, it is preferred that the harness (260) wirelessly communicates an alarm when unfastened from the neck of the patient (305).
  • a second RFID tag can be incorporated into the wrist bracket that most hospitals provide upon admission, with the second RFID tag identifying the patient. Such wrist brackets are unique and can not be effectively removed without destroying the bracelet. Reader (200) would also poll the second RFID tag, and communicate the wrist mounted second RFID along with the identification of the ingested pill.
  • the RFID reader is preferably uni-directional, directed toward the patient's throat, to avoid a "false positive" that can arise if the patient dips the pill in water and then waives the pill near the reader, without ingesting, i.e. swallowing, the pill. While the invention has been shown and described with reference to certain exemplary embodiments of the present invention thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the present invention as defined by the appended claims and equivalents thereof.

Abstract

Disclosed is an apparatus and system for monitoring drug regimen compliance, the system utilizing a Radio Frequency Identification (RfID) tag affixed to a pharmaceutical agent and a wearable RFID reader that identifies a patient. The RFID tag identifies the pharmaceutical agent and the RFID reader wirelessly communicates with a central monitoring system upon ingestion of the pharmaceutical agent.

Description

RFID MONITORING OF DRUG REGIMEN COMPLIANCE
PRIORITY
This application claims priority to U.S. Provisional Application No. 61/041,349, filed April 1, 2008, and to U.S. Provisional Application No. 61/162,704, filed March 24, 2009, the contents of each of which is incorporated herein by reference.
FIELD OF THE INVENTION
The present invention relates generally to electromagnetic tag technology and, more specifically, to the use of Radio Frequency Identification (RFID) tags to ensure and track proper drug regimen compliance and oral medication. BACKGROUND OF THE INVENTION
In conventional hospital and long-term care settings, caregivers must manually supervise patients who are known to avoid ingesting pills, i.e. medicaments and drugs. Even under careful supervision, a patient can deceive a caretaker and avoid taking necessary, often life-preserving, drugs. Pub. No. US 2006/0289640 Al to Mercure, et al., the contents of which is incorporated herein by reference, describes a conventional system in which an RFID electromagnetic tag is positioned in a capsule designed to disperse in the gastrointestinal system. Mercure, et al. relies on a breakdown of the pill in the gastrointestinal system to signal ingestion of the pill. However, the system of Mercure, et al. fails to overcome a significant shortcoming of RFID technology, particularly when a passive RFID chip is used. That is, the high fluid composition of the gastrointestinal system will adversely attenuate the RFID signal, creating a failure to detect ingestion and possibly resulting in undesirable overmedication. There are three possibilities for design of the wireless link. Radiation at high frequencies (UHF) is used for long-range communications in open air, but as the radiation is significantly attenuated by the body, it prohibits this type of wireless link. Inductive coupling at HF (IMHz - 30MHz), used for power coupling of implantable devices, works only for very short distances, up to 10 cm, depending on the size of the coils and their orientation. Near-field UHF provides inherently stronger inductive coupling, and although the attenuation by the body at this frequency range is higher, it provides longer range of detection, up to 1 meter, which is almost on the order of the required distance. A challenge of the design of such a wireless link is the extension of distance that can be achieved through near-field UHF, since due to weak coupling between antennas only a small part of emitted power by an external transmitter antenna reaches the RFID tag antenna. The present invention provides a modified design of an external reader to provide an elongated read range, via a spatially selective external reader, adopting beamforming concepts of antenna design, based on a gradient flow method, such those as described by M. Stanacevic and G. Cauwenberghs, "Micropower Gradient Flow VLSI Acoustic Localizer," IEEE Trans, on Circuits and Systems I: Regular Papers, vol. 52(10), pp. 2148 - 2157, 2005; and by T. Nara. The present invention overcomes the shortcomings of conventional systems by providing a focused ingestion monitoring device by use of electromagnetic tag technology RFID tags to ensure and track proper ingestion of oral medication, which is particularly relevant in hospital and long term care environments. The present invention provides a wireless system for monitoring ingestion of medicine and absorption into the body to insure proper dosage control and usage. To enable pill monitoring, an RFID tag is inserted in or affixed to the pill, and a wireless link between the RFID tag and an external reader is provided that will function when the pill is inside the body.
SUMMARY OF THE INVENTION Preferred embodiments of the present invention overcome the above shortcomings of conventional systems and methods by providing an apparatus for monitoring drug regimen compliance that includes a wearable RFID reader for detecting a Radio Frequency Identification (RFID) tag affixed to an pharmaceutical agent, and for wirelessly communicating with a central monitoring system upon detection of ingestion. The communication includes an identification of the ingested pharmaceutical agent. A database is updated to confirm drug regimen compliance by one or a plurality of patients, in an Internet based tracking system.
BRIEF DESCRIPTION OF THE DRAWINGS
The above and other objects, features and advantages of certain exemplary embodiments of the present invention will be more apparent from the following detailed description taken in conjunction with the accompanying drawings, in which: Fig. 1 is a perspective view of a wearable RFID reader worn around the neck of a patient in accordance with a preferred embodiment of the present invention.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The following detailed description of preferred embodiments of the invention will be made in reference to the accompanying drawings. In describing the invention, explanation about related functions or constructions known in the art are omitted for the sake of clearness in understanding the concept of the invention, to avoid obscuring the invention with unnecessary detail.
In the present invention, an electromagnetic RFID tag is provided on a pill, with the RFID tag providing information about the medicament when polled by the RFID reader. Antennas in the RFID tag and reader could be in different sizes and shapes, with the size of the tag antenna corresponding to the size of the pill, and the external reader fashioned in a manner to accommodate wearing by the patient on his or her body.
In a preferred embodiment, a necklace/pendant is provided for the reader, as shown in Fig. 1. In alternative embodiments, the reader is clipped to the belt or a waistband. With such configuration a maximum achievable distance at which the reader can detect the presence of the RFID tag extends beyond the distance between the RFID tag inside the body and the external reader.
In the present invention, spatial selectivity is possible as the region of the possible location of RFID tag is known, such as in regard to RFID tag localization, where measurements of the first-order spatial gradients of the magnetic field have been demonstrated. See, T. Nara and S. Ando, "Localization of RFID Tags from Measurement of Complex Gradients of Electromagnetic Fields", International Workshop on Networked Sensing Systems (INSS 2004), pp. 63-66, 2004. The differential signal was produced by oppositely wound coils. Standard beamforming phased arrays techniques are not suitable for use in the external reader. The reason is that the performance of beamforming algorithms directly depends on the aperture of the array, and with the decreasing distance between array elements performance degrades, leading to the requirement of a large form factor of the external reader for extended range. A gradient flow method originates from localization of traveling waves. Location of the source can be obtained as an estimation of the source direction through computation of the spatial gradients for the arrays with dimensions smaller than but comparable to the wavelength. In spatial gradient representation, time delays are converted into relative amplitudes of the time- differentiated source signals, if the dimensions of the array are within certain bounds. By computing the spatial gradients, the problem of estimating unknown time delays becomes a computationally less expensive problem of estimation of amplitude modulation, solved in standard least-square fashion. Instead of localization, the gradient flow technique in the proposed spatially selective external reader is used to direct the magnetic energy into certain regions by generating spatial gradients using closely spaced antennas.
The present invention monitors drug regimen compliance by tracking an RFID tag ( 120) affixed to a pill ( 110), i.e. ingestible pharmaceutical agent, via a wearable RFID reader (200), preferably configured as a harness (260) worn by a patient (305), as shown in Fig. 1. The RFID tag (120) includes information identifying the pharmaceutical agent (1 10) and such information is wirelessly transmitted to reader (200), which in turn provides the information, along with an identification of the patient wearing the reader (200), to an Internet based central monitoring system (400), preferably immediately upon ingestion of the pharmaceutical agent (110).
The central monitoring system (400) will, upon communication and confirmation of the ingestion, compare the received information to information stored in a database (410) to determine whether the patient is sufficiently compliant with a prescribed drug regimen. Preferably, the database (410) will identify each of a plurality of harnesses respectively worn by a plurality of patients. Moreover, if a patient ingests an RFID labeled pill that is not prescribed for that patient, or if the patient ingests an excessive number of RFID labeled pills, the central monitoring system (400) will provide an overdose alarm to a caregiver. In a preferred embodiment, an alarm is provided to a caregiver when the database is not updated at a predetermined interval, and the alarm will identify each particular patient who is not in compliance with that patient's prescribed drug regimen. The caretaker will also have access to a report generated at regular intervals showing times that ingestion is detected for each patient among the plurality of patients. In a preferred embodiment, a plurality of antenna layers is provided on the RFID tag (120), with the layers separated by a plurality of coatings that sequentially dissolve during digestion. Preferably the RFID reader (200) detects whether a first layer of the RFID tag (120) has dissolved, which typically occurs upon exposure to liquid when placed in the patient's mouth. For purposes of fraud detection and to confirm proper ingestion, an alert is preferably provided if the first layer is detected as not being dissolved at the time of detection by the RFID reader (200), via an auxiliary antenna having a denser coating that dissolves further along the gastrointestinal tract.
In a preferred embodiment of the present invention, the harness (260) positions the RFID reader (200) adjacent to the patient's throat (310), and the RFID reader (200) is fixably secured to the harness (260). Further, it is preferred that the harness (260) wirelessly communicates an alarm when unfastened from the neck of the patient (305).
As an alternative to fixable securing harness (260), a second RFID tag can be incorporated into the wrist bracket that most hospitals provide upon admission, with the second RFID tag identifying the patient. Such wrist brackets are unique and can not be effectively removed without destroying the bracelet. Reader (200) would also poll the second RFID tag, and communicate the wrist mounted second RFID along with the identification of the ingested pill.
The RFID reader is preferably uni-directional, directed toward the patient's throat, to avoid a "false positive" that can arise if the patient dips the pill in water and then waives the pill near the reader, without ingesting, i.e. swallowing, the pill. While the invention has been shown and described with reference to certain exemplary embodiments of the present invention thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the present invention as defined by the appended claims and equivalents thereof.

Claims

WHAT IS CLAIMED IS:
1. A system for monitoring drug regimen compliance, the system comprising: a Radio Frequency Identification (RFID) tag affixed to a pharmaceutical agent; and a wearable RFID reader that identifies a patient, wherein the RFID tag identifies the pharmaceutical agent and the RFID reader wirelessly communicates with a central monitoring system upon ingestion of the pharmaceutical agent.
2. The system of claim 1, further comprising a database updated by the central monitoring system upon communication of ingestion.
3. The system of claim 1, further comprising a harness worn by a patient.
4. The system of claim 3, wherein the harness positions the RFID reader adjacent to the patient's throat.
5. The system of claim 3, wherein the RFID reader is fixably secured to the harness.
6. The system of claim 5, wherein the harness wirelessly communicates an alarm when unfastened.
7. The system of claim 2, wherein an identification of each of a plurality of harnesses respectively worn by a plurality of patients is wirelessly communicated.
8. The system of claim 7, wherein, upon detection of ingestion of the pharmaceutical agent, the database is updated to indicate drug regimen compliance by the patient.
9. The system of claim 8, wherein an alarm is provided to a caregiver when the database is not updated at a predetermined interval.
10. The system of claim 9, wherein the alarm identifies each particular patient not in compliance with the prescribed drug regimen.
11. The system of claim 10, wherein a report is generated at regular intervals showing times that ingestion is detected for each patient among the plurality of patients.
12. The system of claim 11 , wherein the database includes historical trends for each of the plurality of patients and the report shows deviations from the historical trends.
13. The system of claim 1, wherein the RFID tag is provided with a plurality of layers separated by a plurality of coatings that sequentially dissolve during digestion, and the RFID reader detects which of the plurality of layers has dissolved.
14. The system of claim 1, wherein, if a water soluble layer of the RFID tag is detected as not being dissolved at the time of detection by the RFID reader, an alert is provided to confirm proper ingestion.
15. A wearable monitor comprising a wearable Radio Frequency Identification (RFID) reader for wirelessly communicating with a remote monitoring system upon detection of ingestion of a pharmaceutical agent having an RFID tag affixed thereto.
16. The monitor of claim 15, wherein the RFID reader is affixed to a harness worn by a patient.
17. The monitor of claim 16, wherein the harness positions the RFID reader adjacent to the patient's throat and an alarm is wirelessly communicated when the harness is unfastened from the patient.
18. The system of claim 1, wherein the patient is identified by the RFID polling a second RFID tag affixed to a bracelet worn by the patient.
PCT/US2009/039179 2008-04-01 2009-04-01 Rfid monitoring of drug regimen compliance WO2009146082A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/936,098 US20110163871A1 (en) 2008-04-01 2009-04-01 Rfid monitoring of drug regimen compliance

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US4134908P 2008-04-01 2008-04-01
US61/041,349 2008-04-01
US4982408P 2008-05-02 2008-05-02
US61/049,824 2008-05-02
US16270409P 2009-03-24 2009-03-24
US61/162,704 2009-03-24

Publications (2)

Publication Number Publication Date
WO2009146082A2 true WO2009146082A2 (en) 2009-12-03
WO2009146082A3 WO2009146082A3 (en) 2010-01-21

Family

ID=41377860

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/039179 WO2009146082A2 (en) 2008-04-01 2009-04-01 Rfid monitoring of drug regimen compliance

Country Status (2)

Country Link
US (1) US20110163871A1 (en)
WO (1) WO2009146082A2 (en)

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8836513B2 (en) 2006-04-28 2014-09-16 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
US8847766B2 (en) 2005-04-28 2014-09-30 Proteus Digital Health, Inc. Pharma-informatics system
US8858432B2 (en) 2007-02-01 2014-10-14 Proteus Digital Health, Inc. Ingestible event marker systems
US8868453B2 (en) 2009-11-04 2014-10-21 Proteus Digital Health, Inc. System for supply chain management
US8912908B2 (en) 2005-04-28 2014-12-16 Proteus Digital Health, Inc. Communication system with remote activation
US8932221B2 (en) 2007-03-09 2015-01-13 Proteus Digital Health, Inc. In-body device having a multi-directional transmitter
US8945005B2 (en) 2006-10-25 2015-02-03 Proteus Digital Health, Inc. Controlled activation ingestible identifier
US8956287B2 (en) 2006-05-02 2015-02-17 Proteus Digital Health, Inc. Patient customized therapeutic regimens
US8956288B2 (en) 2007-02-14 2015-02-17 Proteus Digital Health, Inc. In-body power source having high surface area electrode
US8961412B2 (en) 2007-09-25 2015-02-24 Proteus Digital Health, Inc. In-body device with virtual dipole signal amplification
US9014779B2 (en) 2010-02-01 2015-04-21 Proteus Digital Health, Inc. Data gathering system
US9060708B2 (en) 2008-03-05 2015-06-23 Proteus Digital Health, Inc. Multi-mode communication ingestible event markers and systems, and methods of using the same
US9083589B2 (en) 2006-11-20 2015-07-14 Proteus Digital Health, Inc. Active signal processing personal health signal receivers
US9107806B2 (en) 2010-11-22 2015-08-18 Proteus Digital Health, Inc. Ingestible device with pharmaceutical product
US9119918B2 (en) 2009-03-25 2015-09-01 Proteus Digital Health, Inc. Probablistic pharmacokinetic and pharmacodynamic modeling
US9149577B2 (en) 2008-12-15 2015-10-06 Proteus Digital Health, Inc. Body-associated receiver and method
US9149423B2 (en) 2009-05-12 2015-10-06 Proteus Digital Health, Inc. Ingestible event markers comprising an ingestible component
US9198608B2 (en) 2005-04-28 2015-12-01 Proteus Digital Health, Inc. Communication system incorporated in a container
US9235683B2 (en) 2011-11-09 2016-01-12 Proteus Digital Health, Inc. Apparatus, system, and method for managing adherence to a regimen
US9270025B2 (en) 2007-03-09 2016-02-23 Proteus Digital Health, Inc. In-body device having deployable antenna
US9270503B2 (en) 2013-09-20 2016-02-23 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US9268909B2 (en) 2012-10-18 2016-02-23 Proteus Digital Health, Inc. Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
US9271897B2 (en) 2012-07-23 2016-03-01 Proteus Digital Health, Inc. Techniques for manufacturing ingestible event markers comprising an ingestible component
US9320455B2 (en) 2009-04-28 2016-04-26 Proteus Digital Health, Inc. Highly reliable ingestible event markers and methods for using the same
US9415010B2 (en) 2008-08-13 2016-08-16 Proteus Digital Health, Inc. Ingestible circuitry
US9439566B2 (en) 2008-12-15 2016-09-13 Proteus Digital Health, Inc. Re-wearable wireless device
US9439599B2 (en) 2011-03-11 2016-09-13 Proteus Digital Health, Inc. Wearable personal body associated device with various physical configurations
US9577864B2 (en) 2013-09-24 2017-02-21 Proteus Digital Health, Inc. Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance
US9597010B2 (en) 2005-04-28 2017-03-21 Proteus Digital Health, Inc. Communication system using an implantable device
US9597487B2 (en) 2010-04-07 2017-03-21 Proteus Digital Health, Inc. Miniature ingestible device
US9603550B2 (en) 2008-07-08 2017-03-28 Proteus Digital Health, Inc. State characterization based on multi-variate data fusion techniques
US9659423B2 (en) 2008-12-15 2017-05-23 Proteus Digital Health, Inc. Personal authentication apparatus system and method
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US9883819B2 (en) 2009-01-06 2018-02-06 Proteus Digital Health, Inc. Ingestion-related biofeedback and personalized medical therapy method and system
US9962107B2 (en) 2005-04-28 2018-05-08 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US10175376B2 (en) 2013-03-15 2019-01-08 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
US10187121B2 (en) 2016-07-22 2019-01-22 Proteus Digital Health, Inc. Electromagnetic sensing and detection of ingestible event markers
US10223905B2 (en) 2011-07-21 2019-03-05 Proteus Digital Health, Inc. Mobile device and system for detection and communication of information received from an ingestible device
US10398161B2 (en) 2014-01-21 2019-09-03 Proteus Digital Heal Th, Inc. Masticable ingestible product and communication system therefor
US10517506B2 (en) 2007-05-24 2019-12-31 Proteus Digital Health, Inc. Low profile antenna for in body device
US10529044B2 (en) 2010-05-19 2020-01-07 Proteus Digital Health, Inc. Tracking and delivery confirmation of pharmaceutical products
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
US11094407B2 (en) 2019-06-13 2021-08-17 International Business Machines Corporation Electronics miniaturization platform for medication verification and tracking
US11149123B2 (en) 2013-01-29 2021-10-19 Otsuka Pharmaceutical Co., Ltd. Highly-swellable polymeric films and compositions comprising the same
US11158149B2 (en) 2013-03-15 2021-10-26 Otsuka Pharmaceutical Co., Ltd. Personal authentication apparatus system and method
US11529071B2 (en) 2016-10-26 2022-12-20 Otsuka Pharmaceutical Co., Ltd. Methods for manufacturing capsules with ingestible event markers
US11744481B2 (en) 2013-03-15 2023-09-05 Otsuka Pharmaceutical Co., Ltd. System, apparatus and methods for data collection and assessing outcomes

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9449296B2 (en) 2011-08-02 2016-09-20 Kit Check, Inc. Management of pharmacy kits using multiple acceptance criteria for pharmacy kit segments
US8990099B2 (en) 2011-08-02 2015-03-24 Kit Check, Inc. Management of pharmacy kits
US8514067B2 (en) 2011-08-16 2013-08-20 Elwha Llc Systematic distillation of status data relating to regimen compliance
US8981939B2 (en) 2013-05-28 2015-03-17 International Business Machines Corporation System and method for verifying patient compliance
US9171280B2 (en) 2013-12-08 2015-10-27 Kit Check, Inc. Medication tracking
US9498131B1 (en) 2015-07-16 2016-11-22 International Business Machines Corporation Aids for maintaining scheduled medication dosing
US10482292B2 (en) 2016-10-03 2019-11-19 Gary L. Sharpe RFID scanning device
US10692316B2 (en) 2016-10-03 2020-06-23 Gary L. Sharpe RFID scanning device
US20190088354A1 (en) 2017-09-01 2019-03-21 Kit Check, Inc. Identifying discrepancies between events from disparate systems
US20230410972A1 (en) * 2020-12-08 2023-12-21 The Board Of Regents Of The University Of Texas System System and method for remote treatment of drug addiction
JPWO2022186308A1 (en) * 2021-03-02 2022-09-09

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5279607A (en) * 1991-05-30 1994-01-18 The State University Of New York Telemetry capsule and process
US20050131281A1 (en) * 2003-12-15 2005-06-16 Ayer Steven M. Method and apparatus for verification of ingestion
US20060210626A1 (en) * 2005-03-17 2006-09-21 Spaeder Jeffrey A Radio frequency identification pharmaceutical tracking system and method
US20060289640A1 (en) * 2005-05-20 2006-12-28 Mercure Peter K Oral drug compliance monitoring using radio frequency identification tags
US20070213659A1 (en) * 2004-08-27 2007-09-13 Koninklijke Philips Electronics, N.V. Electronically and remotely controlled pill and system for delivering at least one medicament

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6464687B1 (en) * 1999-03-09 2002-10-15 Ball Semiconductor, Inc. Implantable drug delivery system
US20040100376A1 (en) * 2002-11-26 2004-05-27 Kimberly-Clark Worldwide, Inc. Healthcare monitoring system
US20050285746A1 (en) * 2004-06-25 2005-12-29 Sengupta Uttam K Radio frequency identification based system to track consumption of medication
JP5341513B2 (en) * 2005-07-20 2013-11-13 ニール・アール．・イウリアーノ Medication compliance system and related methods
US20070262862A1 (en) * 2006-05-12 2007-11-15 Ichaperone, Llc Monitoring and tracking system

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5279607A (en) * 1991-05-30 1994-01-18 The State University Of New York Telemetry capsule and process
US20050131281A1 (en) * 2003-12-15 2005-06-16 Ayer Steven M. Method and apparatus for verification of ingestion
US20070213659A1 (en) * 2004-08-27 2007-09-13 Koninklijke Philips Electronics, N.V. Electronically and remotely controlled pill and system for delivering at least one medicament
US20060210626A1 (en) * 2005-03-17 2006-09-21 Spaeder Jeffrey A Radio frequency identification pharmaceutical tracking system and method
US20060289640A1 (en) * 2005-05-20 2006-12-28 Mercure Peter K Oral drug compliance monitoring using radio frequency identification tags

Cited By (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10610128B2 (en) 2005-04-28 2020-04-07 Proteus Digital Health, Inc. Pharma-informatics system
US8847766B2 (en) 2005-04-28 2014-09-30 Proteus Digital Health, Inc. Pharma-informatics system
US9597010B2 (en) 2005-04-28 2017-03-21 Proteus Digital Health, Inc. Communication system using an implantable device
US9649066B2 (en) 2005-04-28 2017-05-16 Proteus Digital Health, Inc. Communication system with partial power source
US8912908B2 (en) 2005-04-28 2014-12-16 Proteus Digital Health, Inc. Communication system with remote activation
US9681842B2 (en) 2005-04-28 2017-06-20 Proteus Digital Health, Inc. Pharma-informatics system
US9962107B2 (en) 2005-04-28 2018-05-08 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US9439582B2 (en) 2005-04-28 2016-09-13 Proteus Digital Health, Inc. Communication system with remote activation
US9198608B2 (en) 2005-04-28 2015-12-01 Proteus Digital Health, Inc. Communication system incorporated in a container
US9161707B2 (en) 2005-04-28 2015-10-20 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
US11476952B2 (en) 2005-04-28 2022-10-18 Otsuka Pharmaceutical Co., Ltd. Pharma-informatics system
US10517507B2 (en) 2005-04-28 2019-12-31 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US10542909B2 (en) 2005-04-28 2020-01-28 Proteus Digital Health, Inc. Communication system with partial power source
US9119554B2 (en) 2005-04-28 2015-09-01 Proteus Digital Health, Inc. Pharma-informatics system
US8836513B2 (en) 2006-04-28 2014-09-16 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
US11928614B2 (en) 2006-05-02 2024-03-12 Otsuka Pharmaceutical Co., Ltd. Patient customized therapeutic regimens
US8956287B2 (en) 2006-05-02 2015-02-17 Proteus Digital Health, Inc. Patient customized therapeutic regimens
US11357730B2 (en) 2006-10-25 2022-06-14 Otsuka Pharmaceutical Co., Ltd. Controlled activation ingestible identifier
US8945005B2 (en) 2006-10-25 2015-02-03 Proteus Digital Health, Inc. Controlled activation ingestible identifier
US10238604B2 (en) 2006-10-25 2019-03-26 Proteus Digital Health, Inc. Controlled activation ingestible identifier
US9083589B2 (en) 2006-11-20 2015-07-14 Proteus Digital Health, Inc. Active signal processing personal health signal receivers
US9444503B2 (en) 2006-11-20 2016-09-13 Proteus Digital Health, Inc. Active signal processing personal health signal receivers
US10441194B2 (en) 2007-02-01 2019-10-15 Proteus Digital Heal Th, Inc. Ingestible event marker systems
US8858432B2 (en) 2007-02-01 2014-10-14 Proteus Digital Health, Inc. Ingestible event marker systems
US8956288B2 (en) 2007-02-14 2015-02-17 Proteus Digital Health, Inc. In-body power source having high surface area electrode
US11464423B2 (en) 2007-02-14 2022-10-11 Otsuka Pharmaceutical Co., Ltd. In-body power source having high surface area electrode
US9270025B2 (en) 2007-03-09 2016-02-23 Proteus Digital Health, Inc. In-body device having deployable antenna
US8932221B2 (en) 2007-03-09 2015-01-13 Proteus Digital Health, Inc. In-body device having a multi-directional transmitter
US10517506B2 (en) 2007-05-24 2019-12-31 Proteus Digital Health, Inc. Low profile antenna for in body device
US8961412B2 (en) 2007-09-25 2015-02-24 Proteus Digital Health, Inc. In-body device with virtual dipole signal amplification
US9433371B2 (en) 2007-09-25 2016-09-06 Proteus Digital Health, Inc. In-body device with virtual dipole signal amplification
US9258035B2 (en) 2008-03-05 2016-02-09 Proteus Digital Health, Inc. Multi-mode communication ingestible event markers and systems, and methods of using the same
US9060708B2 (en) 2008-03-05 2015-06-23 Proteus Digital Health, Inc. Multi-mode communication ingestible event markers and systems, and methods of using the same
US9603550B2 (en) 2008-07-08 2017-03-28 Proteus Digital Health, Inc. State characterization based on multi-variate data fusion techniques
US10682071B2 (en) 2008-07-08 2020-06-16 Proteus Digital Health, Inc. State characterization based on multi-variate data fusion techniques
US11217342B2 (en) 2008-07-08 2022-01-04 Otsuka Pharmaceutical Co., Ltd. Ingestible event marker data framework
US9415010B2 (en) 2008-08-13 2016-08-16 Proteus Digital Health, Inc. Ingestible circuitry
US9149577B2 (en) 2008-12-15 2015-10-06 Proteus Digital Health, Inc. Body-associated receiver and method
US9439566B2 (en) 2008-12-15 2016-09-13 Proteus Digital Health, Inc. Re-wearable wireless device
US9659423B2 (en) 2008-12-15 2017-05-23 Proteus Digital Health, Inc. Personal authentication apparatus system and method
US9883819B2 (en) 2009-01-06 2018-02-06 Proteus Digital Health, Inc. Ingestion-related biofeedback and personalized medical therapy method and system
US9119918B2 (en) 2009-03-25 2015-09-01 Proteus Digital Health, Inc. Probablistic pharmacokinetic and pharmacodynamic modeling
US9320455B2 (en) 2009-04-28 2016-04-26 Proteus Digital Health, Inc. Highly reliable ingestible event markers and methods for using the same
US10588544B2 (en) 2009-04-28 2020-03-17 Proteus Digital Health, Inc. Highly reliable ingestible event markers and methods for using the same
US9149423B2 (en) 2009-05-12 2015-10-06 Proteus Digital Health, Inc. Ingestible event markers comprising an ingestible component
US10305544B2 (en) 2009-11-04 2019-05-28 Proteus Digital Health, Inc. System for supply chain management
US9941931B2 (en) 2009-11-04 2018-04-10 Proteus Digital Health, Inc. System for supply chain management
US8868453B2 (en) 2009-11-04 2014-10-21 Proteus Digital Health, Inc. System for supply chain management
US9014779B2 (en) 2010-02-01 2015-04-21 Proteus Digital Health, Inc. Data gathering system
US10376218B2 (en) 2010-02-01 2019-08-13 Proteus Digital Health, Inc. Data gathering system
US9597487B2 (en) 2010-04-07 2017-03-21 Proteus Digital Health, Inc. Miniature ingestible device
US10207093B2 (en) 2010-04-07 2019-02-19 Proteus Digital Health, Inc. Miniature ingestible device
US11173290B2 (en) 2010-04-07 2021-11-16 Otsuka Pharmaceutical Co., Ltd. Miniature ingestible device
US10529044B2 (en) 2010-05-19 2020-01-07 Proteus Digital Health, Inc. Tracking and delivery confirmation of pharmaceutical products
US9107806B2 (en) 2010-11-22 2015-08-18 Proteus Digital Health, Inc. Ingestible device with pharmaceutical product
US11504511B2 (en) 2010-11-22 2022-11-22 Otsuka Pharmaceutical Co., Ltd. Ingestible device with pharmaceutical product
US9439599B2 (en) 2011-03-11 2016-09-13 Proteus Digital Health, Inc. Wearable personal body associated device with various physical configurations
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US11229378B2 (en) 2011-07-11 2022-01-25 Otsuka Pharmaceutical Co., Ltd. Communication system with enhanced partial power source and method of manufacturing same
US10223905B2 (en) 2011-07-21 2019-03-05 Proteus Digital Health, Inc. Mobile device and system for detection and communication of information received from an ingestible device
US9235683B2 (en) 2011-11-09 2016-01-12 Proteus Digital Health, Inc. Apparatus, system, and method for managing adherence to a regimen
US9271897B2 (en) 2012-07-23 2016-03-01 Proteus Digital Health, Inc. Techniques for manufacturing ingestible event markers comprising an ingestible component
US9268909B2 (en) 2012-10-18 2016-02-23 Proteus Digital Health, Inc. Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device
US11149123B2 (en) 2013-01-29 2021-10-19 Otsuka Pharmaceutical Co., Ltd. Highly-swellable polymeric films and compositions comprising the same
US11744481B2 (en) 2013-03-15 2023-09-05 Otsuka Pharmaceutical Co., Ltd. System, apparatus and methods for data collection and assessing outcomes
US11741771B2 (en) 2013-03-15 2023-08-29 Otsuka Pharmaceutical Co., Ltd. Personal authentication apparatus system and method
US10175376B2 (en) 2013-03-15 2019-01-08 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
US11158149B2 (en) 2013-03-15 2021-10-26 Otsuka Pharmaceutical Co., Ltd. Personal authentication apparatus system and method
US10421658B2 (en) 2013-08-30 2019-09-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US11102038B2 (en) 2013-09-20 2021-08-24 Otsuka Pharmaceutical Co., Ltd. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US10498572B2 (en) 2013-09-20 2019-12-03 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US10097388B2 (en) 2013-09-20 2018-10-09 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US9787511B2 (en) 2013-09-20 2017-10-10 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US9270503B2 (en) 2013-09-20 2016-02-23 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US9577864B2 (en) 2013-09-24 2017-02-21 Proteus Digital Health, Inc. Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US10398161B2 (en) 2014-01-21 2019-09-03 Proteus Digital Heal Th, Inc. Masticable ingestible product and communication system therefor
US11950615B2 (en) 2014-01-21 2024-04-09 Otsuka Pharmaceutical Co., Ltd. Masticable ingestible product and communication system therefor
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
US10797758B2 (en) 2016-07-22 2020-10-06 Proteus Digital Health, Inc. Electromagnetic sensing and detection of ingestible event markers
US10187121B2 (en) 2016-07-22 2019-01-22 Proteus Digital Health, Inc. Electromagnetic sensing and detection of ingestible event markers
US11529071B2 (en) 2016-10-26 2022-12-20 Otsuka Pharmaceutical Co., Ltd. Methods for manufacturing capsules with ingestible event markers
US11793419B2 (en) 2016-10-26 2023-10-24 Otsuka Pharmaceutical Co., Ltd. Methods for manufacturing capsules with ingestible event markers
US11094407B2 (en) 2019-06-13 2021-08-17 International Business Machines Corporation Electronics miniaturization platform for medication verification and tracking

Also Published As

Publication number Publication date
WO2009146082A3 (en) 2010-01-21
US20110163871A1 (en) 2011-07-07

Similar Documents

Publication Publication Date Title
US20110163871A1 (en) Rfid monitoring of drug regimen compliance
US7427266B2 (en) Method and apparatus for verification of ingestion
US10102923B1 (en) System, medical item including RFID chip, server and method for capturing medical data
US20100322859A1 (en) Oral drug compliance monitoring using magnetic-field sensors
US9183724B2 (en) System to monitor the ingestion of medicines
US10452875B2 (en) Using RFID devices integrated or included in the packaging of medical devices to facilitate a secure and authorized pairing with a host system
US20190117115A1 (en) System and methods for triggering a radiofrequency transceiver in the human body
CA2616180A1 (en) Oral drug compliance monitoring using sound detection
US20140309505A1 (en) Electronic medication compliance monitoring system and associated methods
WO2007013952A2 (en) Medication compliance system and associated methods
WO2016082404A1 (en) Intelligent security identification device and system
Camacho-Cogollo et al. RFID technology in health care
US11160471B2 (en) Device suitable for being ingested and associated system
US20110319749A1 (en) System and Method for Determining Medical Capsule Location inside a Human Body
US10028118B2 (en) Intelligent security identification apparatus and system
Periyasamy et al. Evaluation of performance of UHF passive RFID system in metal and liquid environment
JP2004212053A (en) Position attitude detection system
US10824822B2 (en) Magnetic tracking for medicine management
US10679018B1 (en) Magnetic tracking for medicine management
Kalra et al. Pharmaceutical applications of radio-frequency identification
US9498131B1 (en) Aids for maintaining scheduled medication dosing
CA2909033C (en) Electronic medication compliance monitoring system and associated methods
Huo et al. A Magneto-Inductive Sensor Based Wireless Pharmaceutical Compliance Monitoring System
TWM534858U (en) Heart rate monitoring bracelet and receiving host with function of urgent calling for emergency care
AU2015243053A1 (en) Electronic medication compliance monitoring system and associated methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09755444

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09755444

Country of ref document: EP

Kind code of ref document: A2